Logo

Spark Signs an Exclusive Global Licensing Agreement with CombiGene for CG01 to Treat Focal Epilepsy

Share this
Spark Signs an Exclusive Global Licensing Agreement with CombiGene for CG01 to Treat Focal Epilepsy

Spark Signs an Exclusive Global Licensing Agreement with CombiGene for CG01 to Treat Focal Epilepsy

Shots:

  • Spark to get exclusive- WW license to develop- manufacture and commercialize CG01 whereas CombiGene will continue to execute aspects of the preclinical program
  • The companies will work together and will leverage their knowledge to address unmet needs for people living with drug-resistant focal epilepsy
  • CG01 is an investigational gene therapy that aims to treat drug resistant focal epilepsy

  | Ref: Spark Therapeutics | Image: Ophthamology Innovation Summit

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions